Pulmonary nodule medical therapy

Pulmonary Nodule Microchapters
Home
Patient Information
Overview
Classification
Causes
Differentiating Pulmonary Nodule from Other Diseases
Epidemiology and Demographics
Screening
Natural history, Complications and Prognosis
Diagnosis
Evaluation of Solitary Pulmonary Nodule
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Case Studies
Case #1
Pulmonary nodule medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pulmonary nodule medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pulmonary nodule medical therapy
CDC on Pulmonary nodule medical therapy
Pulmonary nodule medical therapy in the news
Blogs on Pulmonary nodule medical therapy
Directions to Hospitals Treating Solitary pulmonary nodule
Risk calculators and risk factors for Pulmonary nodule medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

The optimal management approach of solitary pulmonary nodule mainly depends on the nodule size and growth. Other parameters, such as location and distribution may also be helpful. Surgical resection is often recommended among patients with a malignant likelihood of solitary pulmonary nodule. On the other hand, solitary pulmonary nodules with benign features are eligible for periodic CT surveillance.

Medical Therapy

• The optimal management approach of solitary pulmonary nodule mainly depends on the nodule size and growth.
• Other parameters, such as location and distribution may also be helpful.
• The solitary pulmonary nodule risk assessment is useful to determine the likelihood of malignancy and prompt treatment.
• Surgical resection is often recommended among patients with a malignant likelihood of solitary pulmonary nodule.
• On the other hand, solitary pulmonary nodules with benign features are eligible for periodic CT surveillance.

Management Strategies

The algorithm below summarizes the different management strategies for patients with pulmonary nodule:

Solid solitary pulmonary nodule < 8mm

Solid solitary pulmonary nodule > 8mm

Subsolid/part-solid nodule

Multiple

Non-enhanced CT scan (NECT) *Frequency depends on individual risk assesment

Malignancy risk assessment

< 5mm

> 5mm

Each nodule should be assessed individually* CT surveillance and biopsy accordingly

Intermediate Risk Positron emission tomography If positive, request biopsy or surgical excision If negative, serial CT scans* High Risk Biopsy or Surgical excision

CT Surveillance Every 3 months

No additional work-up

Follow-Up and Surveillance

• Guideline treatment and management recommendations for solitary pulmonary nodule include:

• American College of Chest Physicians (ACCP) guidelines
• Fleischner Society guideline

• The table below summarizes the follow-up and surveillance recommendations for solitary pulmonary nodule according to the Fleischner Society guideline:

Recommendations for Follow-up and Management of Nodules <8 mm Detected Incidentally at Non-screening CT
Nodule Size (mm)	Low risk patients	High risk patients
≤ 4	No follow-up needed	Follow-up at 12 months If no change, no further imaging needed
> 4 - 6	Follow-up at 12 months If no change, no further imaging needed	Initial follow-up CT at 6 -12 months and then at 18 - 24 months if no change
> 6 - 8	Initial follow-up CT at 6 -12 months and then at 18 - 24 months if no change	Initial follow-up CT at 3 - 6 months and then at 9 -12 and 24 months if no change
> 8	Follow-up CT at around 3, 9, and 24 months Dynamic contrast enhanced CT, PET, and/or biopsy	Same at for low risk patients

Note: Newly detected indeterminate nodule in persons 35 years of age or older.
* Low risk patients: Minimal or absent history of smoking and of other known risk factors
* High risk patients: History of smoking or of other known risk factors